(ATEC) Alphatec Holdings - Ratings and Ratios
Spinal Implants, Navigation Systems, Biologics, Access Instruments
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 55.4% |
| Value at Risk 5%th | 76.6% |
| Relative Tail Risk | -15.97% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.72 |
| Alpha | 120.53 |
| CAGR/Max DD | 0.30 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.684 |
| Beta | 0.693 |
| Beta Downside | 0.130 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.51% |
| Mean DD | 29.67% |
| Median DD | 31.01% |
Description: ATEC Alphatec Holdings November 11, 2025
Alphatec Holdings, Inc. (NASDAQ: ATEC) is a U.S.-based medical-technology firm that develops, manufactures, and sells spinal-surgery implants, instruments, and related software platforms for both domestic and international markets.
Its flagship Alpha InformatiX suite includes the EOS full-body imaging system, the VEA alignment mobile app, the SafeOp Neural InformatiX intra-operative monitoring solution, and the Valence navigation-and-robotics platform, complemented by the Sigma Prone TransPsoas (PTP) access and positioning systems.
The company’s biologics portfolio features 3D ProFuse osteoconductive scaffolds, AlphaGRAFT demineralized bone matrix (DBM) products, BioCORE synthetic mineral-collagen grafts, and Amnioshield amniotic tissue barriers, all aimed at enhancing spinal fusion outcomes.
Alphatec distributes its products through a hybrid model of independent sales agents and its own direct sales force; the firm was founded in 1990 and is headquartered in Carlsbad, California.
Recent data (Q3 2024) show ATEC’s revenue grew 12% YoY to $215 million, with a gross margin expansion to 58% driven by higher adoption of its navigation-robotics systems; R&D spending remains around 15% of revenue, reflecting the capital-intensive nature of spinal-technology innovation. The broader spine-device market is projected to expand at a CAGR of ~6% through 2030, propelled by an aging U.S. population, increasing prevalence of degenerative disc disease, and favorable reimbursement trends for minimally invasive procedures.
For a deeper, data-driven valuation, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-155.0m TTM) > 0 and > 6% of Revenue (6% = 43.7m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA 26.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 30.08% (prev 36.00%; Δ -5.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 35.1m > Net Income -155.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 1.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (151.4m) change vs 12m ago 5.51% (target <= -2.0% for YES) |
| Gross Margin 69.23% (prev 69.47%; Δ -0.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 94.97% (prev 76.79%; Δ 18.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.85 (EBITDA TTM -52.2m / Interest Expense TTM 40.2m) >= 6 (WARN >= 3) |
Altman Z'' -6.89
| (A) 0.28 = (Total Current Assets 439.8m - Total Current Liabilities 220.8m) / Total Assets 787.2m |
| (B) -1.78 = Retained Earnings (Balance) -1.40b / Total Assets 787.2m |
| warn (B) unusual magnitude: -1.78 — check mapping/units |
| (C) -0.15 = EBIT TTM -114.4m / Avg Total Assets 766.6m |
| (D) -1.81 = Book Value of Equity -1.41b / Total Liabilities 775.7m |
| Total Rating: -6.89 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.58
| 1. Piotroski 3.50pt |
| 2. FCF Yield -0.00% |
| 3. FCF Margin -0.00% |
| 4. Debt/Equity 51.38 |
| 5. Debt/Ebitda -8.34 |
| 6. ROIC - WACC (= -28.61)% |
| 7. RoE data missing |
| 8. Rev. Trend 98.30% |
| 9. EPS Trend 84.15% |
What is the price of ATEC shares?
Over the past week, the price has changed by +5.02%, over one month by +0.34%, over three months by +32.69% and over the past year by +126.97%.
Is ATEC a buy, sell or hold?
- Strong Buy: 4
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ATEC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.6 | 18.9% |
| Analysts Target Price | 24.6 | 18.9% |
| ValueRay Target Price | 22.1 | 6.5% |
ATEC Fundamental Data Overview December 21, 2025
P/E Forward = 166.6667
P/S = 4.083
P/B = 258.3425
Beta = 1.085
Revenue TTM = 728.0m USD
EBIT TTM = -114.4m USD
EBITDA TTM = -52.2m USD
Long Term Debt = 495.0m USD (from longTermDebt, last quarter)
Short Term Debt = 71.1m USD (from shortTermDebt, last quarter)
Debt = 591.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 435.4m USD (from netDebt column, last quarter)
Enterprise Value = 3.41b USD (2.97b + Debt 591.2m - CCE 155.7m)
Interest Coverage Ratio = -2.85 (Ebit TTM -114.4m / Interest Expense TTM 40.2m)
FCF Yield = -0.00% (FCF TTM -14.0k / Enterprise Value 3.41b)
FCF Margin = -0.00% (FCF TTM -14.0k / Revenue TTM 728.0m)
Net Margin = -21.29% (Net Income TTM -155.0m / Revenue TTM 728.0m)
Gross Margin = 69.23% ((Revenue TTM 728.0m - Cost of Revenue TTM 224.0m) / Revenue TTM)
Gross Margin QoQ = 69.87% (prev 69.58%)
Tobins Q-Ratio = 4.33 (Enterprise Value 3.41b / Total Assets 787.2m)
Interest Expense / Debt = 2.18% (Interest Expense 12.9m / Debt 591.2m)
Taxrate = -0.26% (negative due to tax credits) (74.0k / -28.5m)
NOPAT = -114.7m (EBIT -114.4m * (1 - -0.26%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 1.99 (Total Current Assets 439.8m / Total Current Liabilities 220.8m)
Debt / Equity = 51.38 (Debt 591.2m / totalStockholderEquity, last quarter 11.5m)
Debt / EBITDA = -8.34 (negative EBITDA) (Net Debt 435.4m / EBITDA -52.2m)
Debt / FCF = -31.1k (out of range, set to none) (Net Debt 435.4m / FCF TTM -14.0k)
Total Stockholder Equity = 1.49m (last 4 quarters mean from totalStockholderEquity)
RoA = -19.68% (Net Income -155.0m / Total Assets 787.2m)
RoE = -10.4k% (out of range, set to none) (Net Income TTM -155.0m / Total Stockholder Equity 1.49m)
RoCE = -23.03% (EBIT -114.4m / Capital Employed (Equity 1.49m + L.T.Debt 495.0m))
RoIC = -21.10% (negative operating profit) (NOPAT -114.7m / Invested Capital 543.3m)
WACC = 7.51% (E(2.97b)/V(3.56b) * Re(8.57%) + D(591.2m)/V(3.56b) * Rd(2.18%) * (1-Tc(-0.00)))
Discount Rate = 8.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.39%
Fair Price DCF = unknown (Cash Flow -14.0k)
EPS Correlation: 84.15 | EPS CAGR: 72.15% | SUE: 1.07 | # QB: 3
Revenue Correlation: 98.30 | Revenue CAGR: 29.77% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.01 | Chg30d=+0.001 | Revisions Net=-2 | Analysts=4
EPS next Year (2026-12-31): EPS=0.21 | Chg30d=-0.053 | Revisions Net=-1 | Growth EPS=+636.4% | Growth Revenue=+16.6%
Additional Sources for ATEC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle